Information Provided By:
Fly News Breaks for November 14, 2019
EXAS
Nov 14, 2019 | 16:26 EDT
Stifel analyst Daniel Arias initiated coverage of Exact Sciences with a Buy rating and $110 price target. Cologuard momentum remains solid, with 2019 poised to finish with test volumes up 78%, Arias tells investors in a research note. He sees Exact as one of the highest quality names in the Diagnostics space. The risk/reward is skewed towards being long Exact Sciences shares into 2020, says the analyst.
News For EXAS From the Last 2 Days
There are no results for your query EXAS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.